Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)
Idag, 00:24
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)
PR Newswire
NEW YORK, May 18, 2026
Regeneron's executives were optimistic about the potential for fianlimab + Libtayo; when the study failed to produce exepected results, the stock opened down more than 10%.
NEW YORK , May 18, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw significant losses when the stock dropped sharply following the May 16, 2026 disclosure that its Phase 3 melanoma trial of fianlimab + Libtayo failed to meet its primary endpoint versus Keytruda. Investors who lost money on REGN are encouraged to submit their information now to discuss their legal rights . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
During healthcare conference presentations in November and December of 2025, Regeneron executives positively highlighted a delay to its LAG-3 study, assuring investors they "believe this is because the test arms are performing well." Regeneron's Senior Vice President of Investor Relations, Ryan Crowe, noted it was just a mere "slowing of event rates" while confirming to investors management still had "a lot of hope and confidence that fianlimab-plus Libtayo can generate a meaningful differentiation against current standards of care."
Shareholders who purchased Regeneron stock and suffered a loss are encouraged to click here to get more information about the REGN investigation . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the REGN Investigation
Q: Who is eligible to participate in the REGN investigation? A: Investors who purchased REGN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Regeneron Pharmaceuticals made materially false or misleading statements regarding the potential and progress of its Phase 3 melanoma trial. When the trial failure was revealed, the stock price declined sharply.
Q: What do REGN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.
Q: What if I already sold my REGN shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought REGN and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
Tel: (212) 363-7500\
Fax: (212) 363-7171
SOURCE Levi & Korsinsky, LLP
Ämnen i artikeln
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)
Idag, 00:24
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)
PR Newswire
NEW YORK, May 18, 2026
Regeneron's executives were optimistic about the potential for fianlimab + Libtayo; when the study failed to produce exepected results, the stock opened down more than 10%.
NEW YORK , May 18, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw significant losses when the stock dropped sharply following the May 16, 2026 disclosure that its Phase 3 melanoma trial of fianlimab + Libtayo failed to meet its primary endpoint versus Keytruda. Investors who lost money on REGN are encouraged to submit their information now to discuss their legal rights . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
During healthcare conference presentations in November and December of 2025, Regeneron executives positively highlighted a delay to its LAG-3 study, assuring investors they "believe this is because the test arms are performing well." Regeneron's Senior Vice President of Investor Relations, Ryan Crowe, noted it was just a mere "slowing of event rates" while confirming to investors management still had "a lot of hope and confidence that fianlimab-plus Libtayo can generate a meaningful differentiation against current standards of care."
Shareholders who purchased Regeneron stock and suffered a loss are encouraged to click here to get more information about the REGN investigation . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the REGN Investigation
Q: Who is eligible to participate in the REGN investigation? A: Investors who purchased REGN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Regeneron Pharmaceuticals made materially false or misleading statements regarding the potential and progress of its Phase 3 melanoma trial. When the trial failure was revealed, the stock price declined sharply.
Q: What do REGN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.
Q: What if I already sold my REGN shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought REGN and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
Tel: (212) 363-7500\
Fax: (212) 363-7171
SOURCE Levi & Korsinsky, LLP
Ämnen i artikeln
Analys
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
